Quick Answer
4D Molecular Therapeutics, Inc. reported Total Revenue of $85.21 million for fiscal year 2025.
4D Molecular Therapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $85.21M | +230194.6% |
| 2024 | $37.0K | -99.8% |
| 2023 | $20.72M | +562.3% |
| 2022 | $3.13M | -82.7% |
| 2021 | $18.04M | +32.5% |
| 2020 | $13.61M | +94.8% |
| 2019 | $6.99M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $90.0K | +2900.0% | +500.0% |
| June 30, 2025 | $15.0K | +200.0% | +7.1% |
| March 31, 2025 | $14.0K | -50.0% | +366.7% |
| September 30, 2024 | $3.0K | -100.0% | -40.0% |
| June 30, 2024 | $5.0K | -97.9% | -82.1% |
| March 31, 2024 | $28.0K | -90.6% | -99.9% |
| September 30, 2023 | $20.20M | +3940.8% | +8353.6% |
| June 30, 2023 | $239.0K | +47.5% | -19.8% |
- 4D Molecular Therapeutics, Inc. showed an increase of +230194.6% in Total Revenue compared to the prior fiscal year.
- Over the 2019–2025 period, 4D Molecular Therapeutics, Inc.’s total revenue has grown by 1119.7% (from $6.99 million to $85.21 million).
- The most recent figure is from 4D Molecular Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: